anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The risk of iatrogenic disease is often underestimated as a concern in contemporary medical procedures, encompassing tissue and organ transplantation, stem cell therapies, blood transfusions, and the administration of blood-derived products. In this context, despite the prevailing belief that Alzheimer's disease (AD) manifests primarily in familial and sporadic forms, our investigation reveals an unexpected transplantable variant of AD in a preclinical context, potentially indicating iatrogenic transmission in AD patients. Through adoptive transplantation of donor bone marrow stem cells carrying a mutant human amyloid precursor protein (APP) transgene into either APP-deficient knockout or normal recipient animals, we observed rapid development of AD pathological hallmarks. These pathological features were significantly accelerated and emerged within 6-9 months post transplantation and included compromised blood-brain barrier integrity, heightened cerebral vascular neoangiogenesis, elevated brain-associated β-amyloid levels, and cognitive impairment. Furthermore, our findings underscore the contribution of β-amyloid burden originating outside of the central nervous system to AD pathogenesis within the brain. We conclude that stem cell transplantation from donors harboring a pathogenic mutant allele can effectively transfer central nervous system diseases to healthy recipients, mirroring the pathogenesis observed in the donor. Consequently, our observations advocate for genomic sequencing of donor specimens prior to tissue, organ, or stem cell transplantation therapies, as well as blood transfusions and blood-derived product administration, to mitigate the risk of iatrogenic diseases.
Schizophrenia (SCZ) is a heritable complex phenotype whose symptoms can be clustered into three domains: positive symptoms, negative symptoms and cognitive impairments. Constellations of negative symptoms in SCZ are composed of diminished motivation and pleasure, such as asociality, anhedonia, and avolition, or diminished expressivity such as blunted affect and alogia. Negative symptoms are associated with decreased quality of life and poor functional outcomes. Although antipsychotics are generally effective on positive symptoms, they are poorly effective on negative symptoms Currently, there are no licensed targeted medications for negative symptoms. In view of these problems, considerable interest in identifying new treatment targets for negative symptoms has grown over the past decade. Despite intense efforts in brain imaging that have opened new opportunities for addressing these issues, the neurobiological mechanism of negative symptoms remains unclear.

Structural brain measures from magnetic resonance imaging (MRI) are highly heritable and representatively have high reproducibility and low measurement error. Prior neuroimaging researches have consistently shown neuroanatomical abnormalities in the brains of individuals with SCZ, with the most robust and consistent group-level structural differences in widespread reduced volumes of hippocampal thalamus, amygdala and nucleus accumbens. SCZ have been associated with widespread structural brain abnormalities, but results from neuroimaging studies have been inconsistent.
Triferic will be mixed with the liquid bicarbonate concentrate used in the preparation of the hemodialysate solution. This will result in a final Triferic iron concentration in the dialysate of 2 µM (110 µg/L). The patients will receive Triferic over 4 hrs at one hemodialysis session.
Three EP injections of V934 (HD), 1 given every other week over a 5-week period. Following a 4-week observation period, 2 IM injections of V935 (HD) will be administered, 1 given every other week over a 3-week period.
Obtaining the appropriate level of sedation and analgesia in severely injured trauma patients admitted to the intensive care unit (ICU) can be challenging due to the diversity of injuries as well as the breadth of comorbidities present in this population. Clonidine may be a useful adjuvant to traditional analgesics such as opioids and sedatives such as benzodiazepines and propofol. Ventilator dependent trauma patients frequently fail extubation trials secondary to inappropriate sedation, inadequate analgesia or undertreated delirium. Patients that fail extubation for these reasons have a potentially preventable prolonged ventilator, ICU and hospital course. Ventilated trauma patients that meet criteria for our institution's SBT protocol and have the diagnosis of delirium will be considered for the trial if they have a documented failed SBT. We hypothesize treatment of this patient population with transdermal Clonidine will decrease delirium in trauma patients during their ICU stay. Patients enrolled in the treatment group will receive an oral loading dose of Clonidine 0.3 mg and placement of a Clonidine Transdermal system at a dose of 0.3-mg/day (Catapres TTS-3) covered by a patch overlay. In 12 hours the patient will receive a second and final dose of Clonidine 0.3 mg. The placebo group will receive a placebo oral tablet and the overlay patch only and in 12 hours they will receive a second and final placebo tablet. A total of 120 patients will be enrolled, 60 patients in each group. All patients will complete the study at end of Day 14 or upon discharge from the hospital, whichever comes sooner. Ventilator times will be measured in each group as well as the prevalence of delirium by the amount of positive CAM-ICU scores over the course of the trial.
The invention provides a nucleotide sequence of bovine epidermal growth factor (bEGF) and the deduced amino acid sequence of the encoded protein. The invention further provides the nucleotide sequence of mature bEGF and the deduced mature bEGF protein. The invention extends to homologous nucleic acids, proteins, and fragments functionally equivalent to the nucleotide sequence of the bEGF gene and bEGF protein, respectively. Bovine EGF may be expressed in microorganisms such as  E. coli  or  P. pastoris , and plant hosts, such as potato. Activity of recombinant bEGF may be confirmed using a cell proliferation/DNA synthesis assay. Bovine EGF demonstrates utility in livestock and dairy productions as a supplement in farm animal feed to promote growth; to prevent or treat intestinal infections; to stimulate precocious maturation of gut cells to secrete an appropriate spectrum of digestive enzymes; and to increase nutrient absorption.
They contain peptide constituents of M.W. 500-50,000 daltons and are heat resistant up to 80 deg.C are used in cosmetology. They are prepd. by an extraction process which comprises at least one thermo degradation of the starting substance at 37-80 deg.C and at least one sepn. by molecular filtration. The extracts have cell growth factor properties and activating properties for collagenase and they can replace natural biological liq. presently used. They are better tolerated by the skin and more easily penetrate the epiderm.
Subjects aged 60 years or older at the time of re-vaccination, who previously received 1 dose of the GSK1247446A vaccine in study NCT00321763, received 1 dose of adjuvanted GSK1247446A vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
Diabetes Prevention Program (one-treatment group) The diabetes prevention program is a 4-week program that will introduce participants to a regular healthy behaviours that includes exercise and simple dietary strategies. There is no randomization to this program - all individuals enrolled will partake in the same program and will be followed up for 24 months after the program has concluded.
Preparations rich in lipase are prepd. from pancreatic tissue by first autolysing and defatting the minced tissue with a solvent mixt. comprising 80-95 vol. % of a halogenated hydrocarbon (Ia) or aliphatic or aromatic hydrocarbon (Ib), plus 5-20 vol. % of a water. immiscible 4-6C alcohol. (Ia) has density >1.3 and (Ib) density 0.655-0.88 and both have b.pt. at normal press. 47-130 degrees C. The solvent treatment is at 15-20 degrees for 12-40 hrs. using (Ia) or at 15 degrees C for 4 hrs. using (Ib), then the central emulsion layer contg. the tissue water is separated from the top and bottom layers. The enzymes are pptd. from the emulsion with acetone, then dried. Used for treating digestive disorders. Since autolysis and defatting are now done in a single, stage the method is simpler and quicker. The concn. of enzymes in the prod, is increased and the ppte. is recovered in the required particle size.
Severe sepsis and septic shock despite recent advances in surviving sepsis campaign remain encumbered by a high mortality rate close to 30%. One cornerstone of the management of these patients remains the early and appropriate antibiotic administration, , which must be also active at the site of infection. Aminoglycosides are often administered in combination with beta lactams in this context . According to the progress in pharmacokinetic management achieved over the past decade, their safety and efficiency tended to increase but many uncertainties remain. The purpose of the present study is to determine whether administration of aminoglycosides in septic critically ill patient is a risk factor for acute kidney injury.

Study design: This is an open retrospective monocentric cohort study including septic critically ill patients from november 2008 to january 2010. To determine the incidence and the specific risk of nephrotoxicity of aminoglycosides, only hospitalized patients without initial acute kidney injury or with rapidly improving kidney function during the three first days will be included.Primary outcome will be the occurrence of acute kidney injury assessed with the RIFLE classification (Risk, Injury, Failure, Loss, and End-stage kidney disease) from day 4 to day 15. Patients receiving aminoglycosides will be compared with a control group, i.e. not receiving them. We estimated hazard ratios (HR) and 95% confidence intervals (CI) with adjusted and propensity score (PS)-matched Cox-proportional hazards models.
Patients receive pembrolizumab IV over 30 minutes on day 1 and prednisone PO on days 1-5. Patients also receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 2 of course 1 and on day 1 of subsequent courses. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
INTRODUCTION: Stereotactic body radiation therapy (SBRT) is a treatment for patients with early-stage non-small cell lung cancer (ES-NSCLC). Surveillance guidelines vary after treatment. While patients are more likely to locally recur within 2 years of treatment, there remains a paucity of data on the benefit of frequent and long-term surveillance. We evaluated a cohort of NSCLC patients to evaluate surveillance patterns and outcomes.
MATERIALS AND METHODS: Patients with ES-NSCLC treated with SBRT were retrospectively evaluated. Imaging was reviewed after SBRT for evidence of recurrence or new malignancy. The median scan interval (MSI) was calculated as the median number of months between surveillance scans. The MSI between patients with or without new disease was compared by t-test. New disease development and survival between patients with <T2 or >=T2 disease and with or without prior malignancy was compared using χ², Kaplan-Meier analysis, and Gray's test.
RESULTS: A cohort of 168 patients with median follow up of 23.4 months met criteria for review with 50% developing new disease. MSI did not differ between patients with or without new disease. Patients with >=cT2 tumors had worse overall survival and trended towards higher incidence of new disease. New disease continued to occur, even 5 years after treatment.
CONCLUSION: Increased scan frequency did not increase detection of new disease. Patients continued to fail 5 years after treatment. Larger tumors trended toward more frequent failures and those patients experienced worse OS. Surveillance guidelines should be optimized to prevent over surveillance after treatment and to continue long-term surveillance.
3,5-Diarylidenyl-N-substituted-piperid-4-one analogs, and pharmaceutically acceptable derivatives thereof, are useful in the treatment or prevention of disorders including cancer, autoimmune disorders, inflammatory disorders, and fibrotic disorders. The compounds are included in pharmaceutical compositions, and are useful for treating disorders, such as cancer associated with aberrant Stat3 pathway activity. The compositions further include another therapeutic agent, such as an anticancer drug. Such compounds or compositions thereof are used to treat resistant and/or metastatic cancers. Methods also inhibit Stat3 pathway activity in a cell. Other methods are useful for making the pharmaceutical compounds. Synthetic methods are also useful for making the compounds. The compounds and compositions are useful as a fluorescent probe.
Those randomized to this intervention will receive all components described above including the Healthy Together Program, Parenting Training and Promotora support. The wellness coach will try to minimize in-person meetings with FHC professionals each week and space out visits to reduce burden on families.. Families in this group will also be asked to engage in at least 30-60 minutes of additional sessions per week including up to 4 home visits.
Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 or its ligand (PD-1/L1) have expanded the treatment landscape against cancers but are effective in only a subset of patients. Tumor mutation burden (TMB) is postulated to be a generic determinant of ICI-dependent tumor rejection. Here we describe the association between TMB and survival outcomes among microsatellite-stable cancers in a real-world clinicogenomic cohort consisting of 70,698 patients distributed across 27 histologies. TMB was associated with survival benefit or detriment depending on tissue and treatment context, with eight cancer types demonstrating a specific association between TMB and improved outcomes upon treatment with anti-PD-1/L1 therapies. Survival benefits were noted over a broad range of TMB cutoffs across cancer types, and a dose-dependent relationship between TMB and outcomes was observed in a subset of cancers. These results have implications for the use of cancer-agnostic and universal TMB cutoffs to guide the use of anti-PD-1/L1 therapies, and they underline the importance of tissue context in the development of ICI biomarkers.
The invention relates to a health care preparation for improving eyesight and protecting eyesight, which is characterized in that the raw materials of the preparation comprise 12 to 22 portions of extract of blueberry, 4 to 14 portions of lutein, 1 to 10 portions of zinc gluconate, 0.1 to 0.5 portion of vitamin A, 0.01 to 0.1 portion of vitamin B1, 0.01 to 0.1 portion of vitamin B2; the content of  anthocyanin in the extract of blueberry is more than or equal to 25 percent; and the content of the lutein is more than or equal to 5 percent. The preparation comprises sweetener sucrose powder, crystalline fructose, isomalt, mannitol or aspartame whose dosage is 10 to 15 portions. The preparation comprises diluent sodium carboxymethyl starch and microcrystalline cellulose, each of which accounts for 5 to 15 portions, and filler starch which accounts for 10 to 23 portions. The preparation comprises flow agent magnesium stearate and silica gel, each of which accounts for 1 to 5 portions. The preparation procedures are as following: according to the weight portions, qualified raw materials are respectively weighed, and then the raw materials are  screened, mixed, granulated, dried, finished and mixed totally, thereby making qualified semi-finished product; and then the semi-finished product is  tableted and coated, or is filled by the capsule filling engine and filled by the  granule filling machine; and then the preparation can be obtained after the test qualification. With reasonable ratio of composing prescriptions and simple preparation process, the invention effectively relieves asthenopia, protects eyes and improves eyesight.
This is a randomized (treatment assigned by chance), double-blind (patient and investigator will not know what treatment is being given), multicenter, parallel-group, exploratory study in adult Japanese patients with moderate atopic dermatitis. This study will include 3 phases. In the screening phase, patients' eligibility will be determined. During the treatment phase, eligible patients will receive JNJ-39758979, 300 or 100 mg once daily, or placebo (a treatment that looks like JNJ-39758979, but contains no active agent) for up to 6 weeks. Study visits will occur at the end of Weeks 1, 2, 4, and 6. There will be a follow-up visit 4 weeks after dosing is complete. The duration of participation in the study for an individual patient may be up to 14 weeks (including screening). Patient safety will be monitored throughout the study.
The intervention is vasopressor infusion. In this am, 64 surgical and medical patients treated with vasopressor agents in the intensive care unit and developed pressure injury were included.
Arm: Experimental: AQ-13 AQ-13 capsules with 350 mg AQ-13 base per capsule. Two capsules orally on days 1 and 2, one capsule orally on day 3.
Patients chronically taking aspirin (in prophylaxis doses 75-325 mg), with a diagnosis of colorectal polyps ≥ 10 mm in diameter will be enrolled on a routine polypectomy under hospitalization. Meeting the inclusion criteria, after informed consent and a cardiologist consent the patient will receive aspirin/placebo, and The Patient Diary to fill (Visit 1). The patient will be admitted to the Study Center in 6-7 days taking on the aspirin/placebo and prepared for the study (Visit 2). Patient will be under the care of a physician after polypectomy by a minimum of 6 hours. 14 days after polypectomy will be the first control visit, during which the physician will take back patient diary and pack treatment (Visit 3). 30 days after polypectomy will be the second control visit by phone (Visit 4). Patients will be monitored by looking at the end points.
The social group will consist of improvisational party games to foster curiosity and playfulness, use imagery, and encourage non-judgment. Games that may be used include 'Balderdash', 'Wise and Otherwise', 'Charades', 'Pictionary', and 'Tell Me A Story' cards. These games will also use the same core strategies as the dance group. Games will be varied within an hour-long session to incorporate pacing and variability into the social group, akin to the dance group. The social group will occur 2x/week for 1 hour each time and be led by the same instructors who lead the Dance Group, to control for effects of personality of the group leader.
Participants will be randomized into 1:1 allocation, blocked randomization with 20 participants in the PEMF group and 20 participants in the sham group. Each allocation will be assigned with a unique RFID (generated during block randomization by the PEMF supplier service) recognizable by the PEMF machine.
Alveolar bone remodeling following extraction could not be prevented by immediate implant placement. Soft tissue augmentaion techniques have been suggested in order to overcome the alterations of buccal bone during remodeling. Nevertheless, it is still inconclusive whether soft tissue augmentation procedures actually have a protective role in preserving buccal bone thickness in immediate implants.

Aim is to clinically and radiographically assess the effect of soft tissue grafting on buccal bone resorption and pink esthetics around immediately placed implants in maxillary anterior teeth after 24 months following implant placement. 18 non-restorable maxillary anterior teeth randomly assigned into 2 groups: (test group) immediately placed implants with simultaneous vascular interpositional periosteal connective tissue (VIP-CT) grafting versus non-augmented implant sites (control group). Buccal bone changes were assessed at implant placement (0) and at 4,9,12 and 24 months from baseline by specially manufactured device and at 24 months by cone beam computed tomography scans (CBCT). Pink esthetic score (PES) was evaluated at 6, 9, 12 and 24 months intervals. Pain and satisfaction were assessed through questionnaires to the patients.
The present invention relates to the use of cannabidiol (CBD) for the treatment of epileptic seizures associated with Cortical Dysplasia and Cortical Brain Malformation. In a further embodiment the types of seizures include tonic, atonic, and focal without impairment. Preferably the CBD comprises greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) of other cannabinoids. Where the CBD is given concomitantly with one or more other anti-epileptic drugs (AED) including valproic acid, levetiracetam, clobazam, rufinamide, zonisamide or vigabatrin. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day. Preferably the CBD used is in the form of a botanically derived purified CBD, but a synthetically produced CBD can alternatively be used. A method of treating seizures with CBD is also disclosed.
PROBLEM TO BE SOLVED: To stably store and transport an aromatic diamine useful as hair dye for a long period while preventing degradation due to coloring, etc., by pressure-filling an aromatic diamine aqueous solution by means of inert gas into a closed container previously filled with inert gas and then by storing and transporting it in a closed state. SOLUTION: An aqueous solution of an aromatic diamine (pref. 2,5- diaminoalkylbenzene such as 2,5-diaminotoluene) is pressure-filled with inert gas into a closed container previously filled with inert gas (pref. nitrogen gas) and then by storing and transporting it in a closed state pref. at <=35 deg.C. The aqueous solution can contain a reducing substance (pref. ascorbic acid). It is pref. that the oxygen content in the closed container is <=10 ppm and the closed container has a filling port and takeoff in a state separated from each other so as for the contents to be discharged without introducing air from outside atmosphere.
Automated medical analysis may organize medical data based on disease stage and generate a treatment option based on the disease stage. A server comprising a processor circuit and a database may receive medical data. The processor circuit may identify data indicative of a disease stage within the medical data and store the data indicative of the disease stage in the database. The processor circuit may organize the data indicative of the disease stage based on disease stage. The processor circuit may analyze the data indicative of the disease stage to generate a treatment option based on the disease stage. The processor circuit may cause the treatment option and the organized data to be displayed.